Testosterone Cypionate for HIV Wasting: Off-Label Evidence, Risks, and Clinical Tradeoffs

What Is HIV-Associated Wasting Syndrome?

HIV-associated wasting syndrome is defined by the CDC as involuntary weight loss exceeding 10 percent of baseline body weight, accompanied by chronic diarrhea or chronic weakness and fever lasting 30 days or more in the absence of a concurrent illness other than HIV that could explain the findings 1. The syndrome was a leading AIDS-defining diagnosis in the pre-antiretroviral era. It still occurs today despite effective combination antiretroviral therapy (cART).

Modern prevalence estimates vary. A 2019 retrospective analysis published in Clinical Infectious Diseases found that 14 to 20 percent of people living with HIV in the United States still experience clinically significant lean body mass depletion, even with viral suppression 2. Wasting carries independent mortality risk: a loss of more than 5 percent of body cell mass correlates with a two- to sixfold increase in opportunistic infection rates according to data from the Multicenter AIDS Cohort Study 3. Understanding the distinction between fat loss and lean tissue loss matters here, because testosterone targets the latter.

Why Testosterone Cypionate Is Used Off-Label

Testosterone cypionate carries an FDA-approved indication for conditions associated with a deficiency or absence of endogenous testosterone, specifically male hypogonadism due to primary or secondary causes 4. The label does not mention HIV wasting. Any use for wasting is off-label.

The rationale is straightforward. Hypogonadism is common in HIV-positive men, with reported rates between 30 and 50 percent depending on the population studied and the assay threshold used 5. Low testosterone directly contributes to sarcopenia and fatigue. Correcting the deficit with exogenous testosterone restores anabolic signaling in skeletal muscle.

Dr. Shalender Bhasin, a professor of medicine at Brigham and Women's Hospital and a leading investigator in testosterone and body composition research, stated in a 2006 review: "Testosterone administration to HIV-infected men with low testosterone levels increases lean body mass, and may improve quality of life and functional capacity" 6. That observation has been borne out by multiple subsequent trials.

Clinical Trial Evidence for Testosterone in HIV Wasting

The evidence base includes several randomized, placebo-controlled studies. None individually qualifies as a large registrational trial by FDA standards. Taken together, they tell a consistent story.

Bhasin et al., 2000 (N=61). HIV-positive men with weight loss of 5 percent or more were randomized to testosterone enanthate 300 mg weekly (a supraphysiologic dose) or placebo for 16 weeks. The testosterone group gained a mean of 2.6 kg in lean body mass measured by DEXA, compared with a 0.7 kg loss in the placebo group (P<0.001) 7. Strength improved significantly in leg press and chest press exercises.

Grinspoon et al., 1998 (N=51). Hypogonadal HIV-positive men received testosterone cypionate 200 mg IM every two weeks or placebo for 12 weeks. The treatment arm gained 1.6 kg of lean mass versus 0.3 kg in placebo. Quality-of-life scores improved. No serious adverse events occurred during the study period 8.

Kong and Edmonds, 2002 meta-analysis. A Cochrane-style systematic review of anabolic interventions for HIV wasting identified testosterone (both cypionate and enanthate formulations) as producing consistent lean mass gains of 1.5 to 3.2 kg across eligible studies, with moderate-certainty evidence per GRADE criteria 9.

These trials share a limitation: small sample sizes. The largest enrolled only 61 participants. They also studied predominantly men. Data in women with HIV wasting remain sparse, limited to small pilot studies using lower-dose transdermal testosterone or nandrolone decanoate. Clinicians should classify the evidence as moderate certainty for men and very low certainty for women.

How Testosterone Cypionate Compares to FDA-Approved Wasting Therapies

Three agents carry explicit FDA approval for HIV-associated wasting or weight loss.

Megestrol acetate (Megace). A progestational agent approved in 1993. It increases appetite and body weight, but the weight gained is predominantly fat, not lean tissue. A key trial (N=270) showed a mean weight gain of 4.9 kg at 12 weeks, yet DEXA subanalysis confirmed that fat mass accounted for most of the increase 10. Megestrol also suppresses endogenous testosterone, potentially worsening hypogonadism.

Dronabinol (Marinol). A synthetic THC approved for AIDS-related anorexia. Effect sizes are modest. Weight stabilization rather than meaningful gain is the typical outcome.

Somatropin (Serostim). Recombinant human growth hormone approved specifically for HIV-associated wasting. The Serostim trial (N=178) demonstrated a 1.6 kg lean mass gain over 12 weeks at the 6 mg daily dose 11. Cost is the barrier: Serostim can exceed $5,000 per month.

Testosterone cypionate, at a cost of roughly $30 to $80 per month for generic vials, offers a more accessible entry point for lean mass restoration. The tradeoff is the absence of a wasting-specific indication and the associated insurance coverage complexities. Many clinicians prescribe testosterone alongside a diagnosis code for hypogonadism (ICD-10 E29.1) when lab values support it, which simplifies formulary approval.

Dosing Protocols for HIV Wasting

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism recommends testosterone cypionate 75 to 100 mg IM weekly or 150 to 200 mg IM every two weeks as replacement dosing 12. For HIV wasting specifically, published trial protocols have used higher doses.

Most HIV wasting studies administered 200 to 300 mg every one to two weeks, aiming for mid-to-high normal trough testosterone levels (400 to 700 ng/dL). The Bhasin 2000 trial used 300 mg weekly, a frankly supraphysiologic dose that produced testosterone levels well above the reference range and correspondingly larger lean mass gains. This dose also carried greater adverse effect burden.

A practical starting protocol based on the published evidence:

• Baseline labs: Total testosterone, free testosterone, SHBG, CBC, CMP, lipid panel, PSA (men over 40).
• Initial dose: Testosterone cypionate 100 mg IM weekly or 200 mg IM every two weeks.
• Follow-up labs at 8 to 12 weeks: Adjust dose to target trough total testosterone of 400 to 700 ng/dL.
• Reassess lean body mass: DEXA scan at baseline and 24 weeks to quantify response.

The Infectious Diseases Society of America (IDSA) does not include testosterone in its formal HIV treatment guidelines, reflecting the off-label status. The decision to prescribe rests on individual clinical judgment.

Risks and Adverse Effects

Testosterone therapy carries well-characterized risks that require active monitoring. In the HIV wasting population, certain risks deserve extra attention.

Polycythemia. Testosterone stimulates erythropoiesis. Hematocrit levels above 54 percent increase thrombotic risk. The Endocrine Society guideline recommends checking hematocrit at 3 to 6 months and then annually 12. HIV-positive patients on certain antiretrovirals may already have altered hematologic parameters, requiring closer surveillance.

Hepatotoxicity. Injectable testosterone esters are far less hepatotoxic than oral 17-alpha-alkylated androgens. Significant liver injury from cypionate or enanthate injections is rare, but patients with HIV/HCV coinfection (approximately 25 percent of HIV-positive individuals in the U.S.) warrant baseline liver function testing and periodic monitoring 13.

Cardiovascular risk. The TRAVERSE trial (N=5,246), published in 2023 in the New England Journal of Medicine, was the largest cardiovascular safety trial of testosterone replacement. It found no significant increase in major adverse cardiovascular events (MACE) with testosterone versus placebo in hypogonadal men aged 45 to 80 (HR 0.99; 95% CI 0.81 to 1.21) 14. While reassuring, this trial excluded severely immunocompromised populations, and direct extrapolation to advanced HIV disease requires caution.

Fertility suppression. Exogenous testosterone suppresses gonadotropins and spermatogenesis. This is reversible on discontinuation in most cases, but men desiring fertility should discuss alternatives such as clomiphene citrate or human chorionic gonadotropin.

Mood and behavioral effects. Supraphysiologic doses, like the 300 mg weekly regimen used in the Bhasin 2000 trial, carry a higher incidence of irritability and mood swings. Physiologic replacement doses are better tolerated.

Drug interactions with antiretrovirals. Testosterone is metabolized primarily by hepatic CYP3A4. Ritonavir and cobicistat are potent CYP3A4 inhibitors that may increase testosterone exposure. The Endocrine Society advises monitoring testosterone levels more frequently in patients on protease inhibitor-based regimens 12.

Who Is a Good Candidate?

Not every patient with HIV wasting should receive testosterone. The best candidates share several features.

A confirmed low testosterone level is the strongest predictor of response. Men with total testosterone below 300 ng/dL and symptoms of hypogonadism (fatigue, reduced libido, loss of muscle mass) represent the clearest indication. Prescribing testosterone to eugonadal men with wasting is more controversial: the evidence shows lean mass gains even in eugonadal patients at supraphysiologic doses, but the risk-benefit ratio shifts unfavorably.

The 2018 Endocrine Society guideline explicitly states: "We recommend against testosterone therapy in men planning fertility in the near term, men with breast or prostate cancer, hematocrit above 48 percent, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, or a cardiovascular event within the prior 6 months" 12.

Women present a harder case. No testosterone formulation is FDA-approved for women for any indication in the United States. Small studies have explored low-dose transdermal testosterone (150 to 300 mcg/day) in HIV-positive women with wasting, showing modest lean mass gains but also virilization concerns. The International Society for the Study of Women's Sexual Health (ISSWSH) position statement supports testosterone only for hypoactive sexual desire disorder in postmenopausal women, not for wasting 15.

Monitoring During Therapy

A structured monitoring protocol reduces risk and tracks response. Based on the Endocrine Society 2018 guideline and published HIV wasting trial protocols, the minimum schedule is:

• Baseline: Total testosterone, free testosterone, LH, FSH, CBC, CMP, lipid panel, PSA (men over 40), DEXA.
• 6 to 12 weeks: Trough testosterone level, CBC (hematocrit focus), liver function tests.
• 24 weeks: Repeat DEXA for lean body mass quantification, full lab panel.
• Ongoing (every 6 to 12 months): CBC, lipid panel, PSA, liver enzymes, testosterone level.

If hematocrit rises above 54 percent, the guideline recommends dose reduction, switching to a topical formulation (which produces lower hematocrit spikes), or therapeutic phlebotomy 12.

The Bottom Line on Off-Label Use

Testosterone cypionate for HIV-associated wasting occupies a specific clinical niche. The data show clear lean body mass benefits in hypogonadal HIV-positive men. The gains are modest (2 to 3 kg over 12 to 24 weeks) but clinically meaningful in a population where lean tissue loss predicts survival. The drug is inexpensive and widely available. It is not, and likely will not become, FDA-approved for this indication because the commercial incentive to fund a registrational wasting trial for a generic drug does not exist.

Clinicians prescribing testosterone cypionate off-label for HIV wasting should document the rationale, confirm hypogonadism with morning testosterone levels, obtain informed consent for off-label use, and follow the Endocrine Society's monitoring framework. The 2023 TRAVERSE trial's neutral cardiovascular findings provide reassurance, but the HIV-specific evidence base remains limited to small trials from the late 1990s and early 2000s. Patients on CYP3A4-inhibiting antiretrovirals like ritonavir need tighter lab follow-up to avoid supratherapeutic testosterone levels and polycythemia.